| Study group | |||
---|---|---|---|---|
Control | Treatment | |||
n = 261 | n = 256 | |||
n | (%) | n | (%) | |
Age | Â | Â | Â | Â |
< 50 | 56 | 21.5 | 96 | 37.5 |
≥ 50 | 205 | 78.5 | 160 | 62.5 |
Median (range) | 59 | (22–87) | 55 | (22–86) |
Gender | Â | Â | Â | Â |
Male | 142 | 54.4 | 123 | 48.0 |
Female | 119 | 45.6 | 133 | 52.0 |
Clinical Service | Â | Â | Â | Â |
Medical Oncology | 144 | 55.2 | 151 | 59.0 |
Radiation Oncology | 87 | 33.3 | 86 | 33.6 |
HSCT | 30 | 11.5 | 19 | 7.4 |
Working Status | Â | Â | Â | Â |
Missing | 33 | 12.6 | 16 | 6.3 |
Not Working | 72 | 27.6 | 81 | 31.6 |
Working full/part time | 156 | 59.8 | 159 | 62.1 |
Cancer Type | Â | Â | Â | Â |
Bladder | 8 | 3.1 | 5 | 2.0 |
Breast | 70 | 26.8 | 81 | 31.6 |
Colorectal | 21 | 8.0 | 28 | 10.9 |
Gastrointestinal, not colorectal | 47 | 18 | 47 | 18.3 |
Head and Neck | 15 | 5.7 | 12 | 4.7 |
Leukemia/lymphoma/myeloma | 41 | 15.7 | 30 | 11.8 |
Prostate | 48 | 18.4 | 49 | 19.1 |
Other | 21 | 8 | 16 | 6.3 |
Missing | 8 | 3.1 | 5 | 1.9 |
Stage | Â | Â | Â | Â |
0 | 8 | 3.1 | 2 | 0.8 |
1 | 44 | 16.9 | 39 | 15.2 |
2 | 60 | 23.0 | 67 | 26.2 |
3 | 38 | 14.6 | 56 | 21.9 |
4 | 73 | 28.0 | 65 | 25.4 |
N/A | 3 | 1.1 | 0 | 0 |
Missing | 35 | 13.4 | 27 | 10.5 |
SDS-15 (T2) mean (SD) | 27.0 (8.12) | 26.6 (7.73) |